+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
Recurrent Or Metastatic Head And Neck Cancer Market - Product Thumbnail Image

Recurrent Or Metastatic Head And Neck Cancer Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Neuroendocrine Tumors Market - Product Thumbnail Image

Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Gastric Neuroendocrine Tumors Market - Product Thumbnail Image

Gastric Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Synovial Sarcoma Pipeline Analysis Report - Product Thumbnail Image

Synovial Sarcoma Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Head and Neck Cancer (HNC) Pipeline Analysis Report - Product Thumbnail Image

Head and Neck Cancer (HNC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
AXL Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Head And Neck Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Hepatocellular Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatocellular Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 230 Pages
  • Global
From
Advanced Liver Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Liver Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
From
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
TGF-Beta-1 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

TGF-Beta-1 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more